Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial

Summary: Background: BNT162b2, an mRNA vaccine against COVID-19, is being utilised worldwide, but immunogenicity and safety data in Chinese individuals are limited. Methods: This phase 2, randomised, double-blind, placebo-controlled trial included healthy or medically stable individuals aged 18–85...

Full description

Bibliographic Details
Main Authors: Ai-Min Hui, Jingxin Li, Li Zhu, Rong Tang, Huayue Ye, Mei Lin, Lei Ge, Xiyuan Wang, Fuzhong Peng, Zhenggang Wu, Xiling Guo, Yunfeng Shi, Hongxing Pan, Jiahong Zhu, Zhizhou Song, Jingjun Qiu, Wei Wang, Jianfei Zheng, Orkun Ozhelvaci, Svetlana Shpyro, Meghan Bushway, Evelyna Derhovanessian, Marie-Cristine Kühnle, Ulrich Luxemburger, Alexander Muik, Yoana Shishkova, Zakaria Khondker, Simin Hu, Eleni Lagkadinou, Uğur Şahin, Özlem Türeci, Fengcai Zhu
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:The Lancet Regional Health. Western Pacific
Subjects:
BNT162b2 mRNA vaccine
COVID-19
Intramuscular injection
Messenger RNA
Neutralising antibodies
SARS-CoV-2
Online Access:http://www.sciencedirect.com/science/article/pii/S2666606522002012

Internet

http://www.sciencedirect.com/science/article/pii/S2666606522002012

Similar Items